Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . Wuxi Biologics Global Solution Provider WUXI BIOLOGICS ( CAYMAN ) INC . 藥 明 生物 技術 有限公司 * ( Incorporated in the Cayman Islands with limited liability ) ( Stock Code : 2269 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30 , 2021 FINANCIAL HIGHLIGHTS Six months ended June 30 , 2021 2020 Change RMB million RMB million Revenue 4,406.8 1,944.1 126.7 % Gross profit 2,296.8 787.3 191.7 % Gross profit margin 52.1 % 40.5 % Net profit 1,882.8 730.7 157.7 % Net profit margin 42.7 % 37.6 % Net profit attributable to owners of the Company 1,842.1 736.1 150.3 % Margin of net profit attributable to owners of the Company 41.8 % 37.9 % Adjusted net profit 1,812.1 667.0 171.7 % Adjusted net profit margin 41.1 % 34.3 % Adjusted net profit attributable to owners of the Company 1,768.7 672.4 163.0 % Margin of adjusted net profit attributable to owners of the Company 40.1 % 34.6 % RMB RMB ( Note ) Earnings per share Adjusted earnings per share Basic 0.44 0.19 131.6 % Diluted 0.42 0.18 133.3 % Basic 0.43 0.17 152.9 % Diluted 0.40 0.16 150.0 % The Board resolved not to declare any interim dividend for the six months ended June 30 , 2021 . Note : The authorized and issued shares of the Company were subdivided on the basis that every one ( 1 ) issued share is subdivided into three ( 3 ) subdivided shares ( the " Share Subdivision " ) , which became effective on November 16 , 2020 . Basic and diluted earnings per share were stated after taking into account the effect of the Share Subdivision . Comparative figures have also been restated on the assumption that the Share Subdivision had been effective in prior interim period . -1-